In Vitro Activities of 21 Antimicrobial Agents Alone and in Combination with Aminoglycosides or Fluoroquinolones against Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates Causing Bacteremia | Zendy

Min Kyeong | Zendy; CheolIn Kang | Zendy; Kim Ys | Zendy; Sun Young Cho | Zendy; Young Eun Ha | Zendy; Yu Mi Wi | Zendy; Doo Ryeon Chung | Zendy; Kyong Ran Peck | Zendy; JaeHoon Song | Zendy

Open Access

In Vitro Activities of 21 Antimicrobial Agents Alone and in Combination with Aminoglycosides or Fluoroquinolones against Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates Causing Bacteremia

Author(s) -

Min Kyeong,

CheolIn Kang,

Kim Ys,

Sun Young Cho,

Young Eun Ha,

Yu Mi Wi,

Doo Ryeon Chung,

Kyong Ran Peck,

JaeHoon Song

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01121-15

Subject(s) - amikacin , cefepime , ciprofloxacin , piperacillin , antimicrobial , microbiology and biotechnology , tazobactam , ceftazidime , bacteremia , piperacillin/tazobactam , medicine , aminoglycoside , combination therapy , antibiotics , biology , imipenem , pharmacology , antibiotic resistance , bacteria , pseudomonas aeruginosa , genetics

We evaluated thein vitro activity of various antimicrobials alone and in combination against 291 extended-spectrum-β-lactamase-producingEscherichia coli (ESBL-EC) isolates causing bacteremia in South Korean hospitals. Ceftazidime, cefepime, and piperacillin-tazobactam in combination with amikacin showed greater activity than found in combination with ciprofloxacin. In settings with a high prevalence of ESBL-producing pathogens, combination aminoglycoside antimicrobial therapy, especially with amikacin, may be considered for empirical therapy against suspected Gram-negative sepsis as a carbapenem-saving strategy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research